Sagar Cements clears NCLT filing route for Andhra merger

Sagar Cements Limited can file its proposed merger with Andhra Cements Limited before the National Company Law Tribunal after BSE issued no adverse observations on November 5, 2026 and NSE issued a no-objection letter on November 6, 2026. Each Regulation 37 letter is valid for six months, while the scheme still needs further approvals.

What have BSE and NSE cleared for Sagar Cements?

BSE and NSE have completed their review of Sagar Cements’ draft amalgamation scheme under Regulation 37 of the Securities and Exchange Board of India’s Listing Obligations and Disclosure Requirements Regulations, 2015. BSE’s November 5, 2026 letter recorded no adverse observations on matters affecting listing, delisting and continuous-listing requirements, while NSE’s November 6, 2026 letter conveyed no objection to enable an NCLT filing.

The scheme proposes the amalgamation of Andhra Cements Limited, the transferor company, with and into Sagar Cements, the transferee company, under Sections 230 to 232 of the Companies Act, 2013. Sagar Cements disclosed both letters on November 6, 2026 under Regulation 30, moving the proposal beyond the exchange-observation stage but not completing the transaction.

The two exchange outcomes use different wording and were issued one day apart. BSE said it had no adverse observations, whereas NSE said it had no objection, but both expressly limit their positions to the regulatory review of the draft scheme. Both exchanges also state that their letters do not amount to an assessment of the scheme’s financial soundness or an endorsement of statements or opinions in the submitted documents.

When must Sagar Cements file the scheme with NCLT?

Sagar Cements must submit the scheme to the National Company Law Tribunal, or NCLT, within six months of the respective exchange letters. BSE’s validity period runs from November 5, 2026, and NSE’s runs from November 6, 2026, meaning the company must meet the applicable six-month windows to rely on the Regulation 37 observations.

The next filing is a tribunal petition rather than a final merger order. Sagar Cements said in its November 6, 2026 disclosure that the proposal remains subject to statutory and regulatory approvals, including approval from the NCLT. NSE similarly said its November 6 letter should not be treated as approval under other laws, regulations, rules or bye-laws that may require separate consents.

The NCLT petition must include the observations issued by SEBI, BSE and NSE, and the companies must bring those observations to the tribunal’s attention. NSE additionally required a compliance-status report covering every observation-letter point through its electronic filing path, NEAPS, after the November 6, 2026 letter.

What approvals and conditions remain for the Andhra Cements merger?

The merger remains conditional on NCLT proceedings, shareholder and creditor processes where required, and compliance with the Companies Act and applicable SEBI requirements. BSE’s November 5, 2026 letter said the scheme must expressly remain subject to no-objection certificates from lending scheduled commercial banks or financial institutions, in line with the relevant SEBI master circular.

Both exchange letters require a report on complaints to be received, examined and addressed before the scheme is acted upon. They also require additional information submitted after the draft-scheme filing to be displayed on the listed company’s and, where specified, exchange websites. Any equity shares issued under the scheme must be in dematerialised form.

SEBI’s October 30, 2026 comments, reproduced in the exchange letters, require disclosures to the NCLT and shareholders about ongoing adjudication or recovery proceedings, prosecutions and other enforcement actions, if any, involving the companies, promoters and directors. The shareholder disclosures must also cover pending actions involving the entities, promoters, directors and key managerial personnel, if any.

What will Sagar Cements shareholders need to receive?

Sagar Cements must give shareholders a detailed explanation of the merger’s need, rationale, business synergies, shareholder impact and cost-benefit analysis when seeking approval under Sections 230 to 232. The November 5 and November 6, 2026 exchange letters also require disclosure of potential benefits and risks, financial implications for promoters and public shareholders, and the transferee company’s future growth prospects after the amalgamation.

The shareholder materials must identify the registered valuer responsible for the valuation report and the merchant banker responsible for the fairness opinion. They must explain the methods considered for the share-swap ratio, the rationale for those methods and the basis for the final ratio. The source does not disclose the ratio itself in these observation letters.

The prescribed disclosures also include pre- and post-scheme shareholding of the transferor and transferee companies as of the shareholder-meeting notice date, with reasons for changes from the draft-scheme filing if any. In addition, shareholders must receive three years of revenue, profit after tax, or PAT, and earnings before interest, depreciation, tax and amortisation, or EBIDTA, for both companies.

The notices must further provide the value of Andhra Cements’ assets and liabilities proposed to transfer to Sagar Cements and the transferee company’s post-merger balance sheet. They must cover capital built up since incorporation and in the latest three years. These requirements mean the shareholder package, rather than the November 2026 exchange letters, is intended to provide the operating and financial detail behind the merger.

What restrictions apply after the exchange review?

Sagar Cements cannot freely revise the draft scheme after the November 2026 exchange review. BSE and NSE said changes other than those mandated by regulators, authorities or tribunals require SEBI’s specific written consent. The observation letters and SEBI comments must therefore be incorporated into the NCLT petition under the existing scheme process.

Both letters require that all liabilities of Andhra Cements transfer to and vest in Sagar Cements under the scheme. They also require financial information in the scheme, including financials used for the valuation report, to be no more than six months old. This creates a continuing disclosure condition as the companies move from the November 2026 exchange stage to shareholder and tribunal proceedings.

BSE reserved the right to withdraw its no-adverse-observations position at any stage if information is incomplete, incorrect, misleading or false, or if applicable requirements are contravened. NSE reserved a similar right to raise objections. Those reservations accompany the six-month validity periods beginning on November 5 and November 6, 2026, respectively.

Conclusion

The BSE and NSE letters allow Sagar Cements to take the proposed absorption of Andhra Cements to the NCLT, which is a material procedural step but not final approval. The one-day difference between BSE’s November 5, 2026 letter and NSE’s November 6, 2026 letter does not change the central outcome: both exchanges have completed their Regulation 37 review subject to stated conditions.

The next point to watch is an NCLT filing within the six-month periods specified by BSE and NSE. Before the scheme can progress, the disclosed process still calls for current financial and valuation disclosures, complaint handling, applicable lender no-objection certificates, creditor and shareholder procedures, and a petition incorporating the SEBI and exchange observations.